JARID2 Inhibition Reprograms Human Hematopoietic Progenitor Cells To Enhance Bone Marrow Transplantation

Area of Science:

• Hematology
• Stem Cell Biology
• Epigenetics

Background:

• Hematopoietic stem cell transplantation (HSCT) is crucial for treating blood disorders.
• Umbilical cord blood (UCB) is a vital source of hematopoietic stem and progenitor cells (HSPCs) for HSCT.
• Limited HSPC numbers in UCB restrict its clinical application.

Purpose of the Study:

• To investigate if JARID2 inhibition can enhance the function of human HSPCs.
• To explore the mechanisms underlying JARID2's role in HSPC regulation.

Main Methods:

• Constitutive and transient knockdown of JARID2 in human HSPCs.
• In vitro and in vivo functional assays.
• Gene expression analysis and immunophenotyping.

Main Results:

• JARID2 knockdown increased the number and functionality of human HSPCs.
• The observed phenotype was independent of Polycomb Repressive Complex 2 (PRC2) co-factor activity.
• JARID2 inhibition induced a quiescent, self-renewal gene expression program via STAT1 upregulation and MHC class II expression.

Conclusions:

• JARID2 inhibition is a novel strategy to expand functional UCB-derived HSPCs ex vivo.
• This approach offers a reversible method to enhance HSPC potential.
• Findings may improve access to stem cell transplantation for more patients.